Scalp

DGAP-News: Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

Thursday, October 14, 2021 - 12:08pm

Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.

Key Points: 
  • Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.
  • Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.
  • The additional funding will be used to support ongoing clinical studies and to further advance EASEE(R), an implantable bioelectric brain stimulation system that explores novel approaches to treating epilepsy.
  • Angela Liedler, MD, CEO of Precisis AG, is thrilled: "This funding round is an important step in the advancement of bioelectric brain stimulation.

Venus Concept Appoints Ross J. Portaro as President of Global Sales

Tuesday, October 12, 2021 - 12:30pm

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021.

Key Points: 
  • TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021.
  • Mr. Portaro joined Venus Concept as Vice President of EMEA in May, 2021, responsible for developing the sales strategy and managing all sales and utilization activity via direct and distribution sales channels in the region.
  • Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD.

WEN® By Chaz Dean Named A 2021 QVC® Customer Choice® Beauty Awards Winner

Thursday, October 7, 2021 - 2:39pm

The QVC customers have voted for their favorite beauty products and WEN By Chaz Dean has won multiple categories.

Key Points: 
  • The QVC customers have voted for their favorite beauty products and WEN By Chaz Dean has won multiple categories.
  • The annual QVC Customer Choice Beauty Awards recognize customer favorites in more than 45 categories across cosmetics, hair care, skin care, devices and more.
  • These award-winning products will be featured in QVC Customer Choice Beauty Awards digital shop and will also be badged with the QVC Customer Choice Beauty Awards logo on QVC.com.
  • As a Customer Choice Beauty Award winner, WEN By Chaz Dean continues to foster this engaging community of dedicated customers.

Introducing Fantasia's Natural Avocado Cilantro Haircare Line

Thursday, October 7, 2021 - 2:15pm

PARAMUS, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Fantasia Inc. introduces it's Natural Avocado Cilantro line of products, which protects hair from root to ends.

Key Points: 
  • PARAMUS, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Fantasia Inc. introduces it's Natural Avocado Cilantro line of products, which protects hair from root to ends.
  • The products are made with 100% organic avocado oil, a natural moisturizer containing vitamins and a high content of Omega 3 & 6 fatty acids, and cilantro, which provides proteins and pH balances hair and scalp.They work together to amplifyoverall hair health.Bond building Fiberhance technology rebuilds the keratin structure of hair, making it 3 times stronger.
  • For hair that's yearning for moisture or for those simply wanting to keep up with their daily maintenance, look no further: Fantasia's avocado cilantro line has everyone covered.
  • Head to www.fantasiahaircare.com or email marina@fantasiahaircare.com to learn more about the Avocado Cilantro Haircare line.

Garnier & Walmart Join Forces To Co-Create An Exclusive Haircare Collection, Garnier Fructis Pure Clean Hair Reset

Tuesday, October 5, 2021 - 3:00pm

NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Garnier and Walmart have teamed up to introduce a new exclusive haircare line focused on the scalp the Garnier Fructis Pure Clean Hair Reset collection.

Key Points: 
  • NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Garnier and Walmart have teamed up to introduce a new exclusive haircare line focused on the scalp the Garnier Fructis Pure Clean Hair Reset collection.
  • The Garnier Fructis Pure Clean Hair Reset collection is available exclusively at Walmart, in more than 4,200 stores and at Walmart.com.
  • Our consumers are interested in haircare products inspired by their everyday skincare because they know those ingredients deliver on clean.
  • The launch of the Fructis Pure Clean Hair Reset collection expands our selection of on-trend products with sophisticated formulas and ingredients that deliver impressive hair and scalp benefits at an incredible value."

Venus Concept to Release Third Quarter of Fiscal Year 2021 Financial Results on November 12, 2021

Monday, October 4, 2021 - 9:05pm

TORONTO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Friday, November 12, 2021.

Key Points: 
  • TORONTO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Friday, November 12, 2021.
  • Management will host a conference call at 8:00 a.m. Eastern Time on November 12, 2021 to discuss the results of the quarter with a question and answer session.
  • Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD.

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

Monday, October 4, 2021 - 1:00pm

Roflumilast cream, a non-steroidal treatment intended for chronic use, would be the first and only topical PDE4 inhibitor for psoriasis, if approved.

Key Points: 
  • Roflumilast cream, a non-steroidal treatment intended for chronic use, would be the first and only topical PDE4 inhibitor for psoriasis, if approved.
  • Roflumilast cream (ARQ-151) is a once-daily topical formulation of roflumilast, a highly potent and selective inhibitor of phosphodiesterase type 4 (PDE4), an enzyme that drives overactive immune responses.
  • If approved, roflumilast cream will be the first and only topical PDE4 inhibitor approved for psoriasis and an important non-steroidal treatment option for the millions of individuals struggling with plaque psoriasis.
  • Roflumilast Cream is a topical cream formulation of a highly potent and selective PDE4 inhibitor, roflumilast.

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

Thursday, September 30, 2021 - 1:30pm

In addition, in two separate Phase 2 studies, topical roflumilast foam showed a robust and rapid reduction of itch in scalp and body psoriasis and seborrheic dermatitis.

Key Points: 
  • In addition, in two separate Phase 2 studies, topical roflumilast foam showed a robust and rapid reduction of itch in scalp and body psoriasis and seborrheic dermatitis.
  • These data were presented at the annual European Academy of Dermatology and Venereology (EADV) Congress (Sept 29 Oct 2).
  • Itch is the most frequently reported symptom associated with dermatologic conditions such as plaque psoriasis, scalp psoriasis and seborrheic dermatitis, severely impacting patients quality of life.
  • Meaningfully impacting symptoms that matter most to patients, such as itch, is at the core of Arcutis mission.

Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud

Wednesday, September 29, 2021 - 10:00am

The Wyss Center announced today the CE (Conformit Europenne) mark Class I medical device for its Epios Cloud software.

Key Points: 
  • The Wyss Center announced today the CE (Conformit Europenne) mark Class I medical device for its Epios Cloud software.
  • View the full release here: https://www.businesswire.com/news/home/20210929005365/en/
    Epios Cloud is a web-based application for online storage, processing and review of neural signals, including ultra-long-term data.
  • Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years.
  • The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjrg Wyss in 2014.

Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis

Monday, September 27, 2021 - 1:00pm

BUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall (Almirall, S.A., BME: ALM), has launched Klisyri® (tirbanibulin) in Germany and the UK. Klisyri received approval by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults.

Key Points: 
  • Klisyri received approval by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults.
  • We are extremely pleased to see Klisyri launching in these two major European markets by our partner Almirall, said Dr. Johnson Lau, Chief Executive Officer of Athenex.
  • The launch of Klisyri represents an option with acceptable tolerability and shorter duration of treatment for dermatologists to provide their patients.
  • Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp.